Rize Oncology Inc., a pharmaceutical company, develops oncology therapies for the treatment of soft tissue sarcoma. The company develops STS-201, a small molecule drug candidate for the treatment of soft tissue sarcoma, as well as other types of cancers and proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.